[go: up one dir, main page]

RU2001126300A - CRYSTALLINE MODIFICATION C 8-CYAN-1-CYCLOPROPYL-7 (1S, 6S-2,8-DIAZABICYCLO [4.3.0] NONAN-8-IL) -6-FLUOR-1,4-DIGIDRO-4-OXO-3- Quinoline Carboxylic Acid - Google Patents

CRYSTALLINE MODIFICATION C 8-CYAN-1-CYCLOPROPYL-7 (1S, 6S-2,8-DIAZABICYCLO [4.3.0] NONAN-8-IL) -6-FLUOR-1,4-DIGIDRO-4-OXO-3- Quinoline Carboxylic Acid

Info

Publication number
RU2001126300A
RU2001126300A RU2001126300/04A RU2001126300A RU2001126300A RU 2001126300 A RU2001126300 A RU 2001126300A RU 2001126300/04 A RU2001126300/04 A RU 2001126300/04A RU 2001126300 A RU2001126300 A RU 2001126300A RU 2001126300 A RU2001126300 A RU 2001126300A
Authority
RU
Russia
Prior art keywords
ccdc
modification
nonan
diazabicyclo
cyan
Prior art date
Application number
RU2001126300/04A
Other languages
Russian (ru)
Other versions
RU2248356C2 (en
Inventor
Хуберт Раст
Томас Химмлер
Original Assignee
Байер Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19908449A external-priority patent/DE19908449A1/en
Application filed by Байер Акциенгезельшафт filed Critical Байер Акциенгезельшафт
Publication of RU2001126300A publication Critical patent/RU2001126300A/en
Application granted granted Critical
Publication of RU2248356C2 publication Critical patent/RU2248356C2/en

Links

Claims (7)

1. 8-Циан-1-циклопропил-7-(1S,6S-2,8-диазабицикло[4.3.0]нонан-8-ил)-6-фтор-1,4-дигидро-4-оксо-3-хинолинкарбоновая кислота (CCDC) кристаллической модификации С, отличающаяся тем, что она имеет рентгено-дифрактограмму со следующими рефлексами (2 тэта) с повышенной и средней интенсивностью.1. 8-Cyan-1-cyclopropyl-7- (1S, 6S-2,8-diazabicyclo [4.3.0] nonan-8-yl) -6-fluoro-1,4-dihydro-4-oxo-3- quinoline carboxylic acid (CCDC) of crystalline modification C, characterized in that it has an X-ray diffraction pattern with the following reflexes (2 theta) with high and medium intensity. 2θ (2 тэта)2θ (2 theta)
5,75.7
12,612.6
15,515,5
17,217,2
20,220,2
26,426,4
2727
2. 8-Циан-1-циклопропил-7-(1S,6S-2,8-диазабицикло[4.3.0]нонан-8-ил)-6-фтор-1,4-дигидро-4-оксо-3-хинолинкарбоновая кислота (CCDC) кристаллической модификации С, отличающаяся тем, что она имеет рентгено-дифрактограмму со следующими рефлексами (2 тэта) с повышенной и средней интенсивностью2. 8-Cyan-1-cyclopropyl-7- (1S, 6S-2,8-diazabicyclo [4.3.0] nonan-8-yl) -6-fluoro-1,4-dihydro-4-oxo-3- quinoline carboxylic acid (CCDC) crystalline modification C, characterized in that it has an X-ray diffraction pattern with the following reflexes (2 theta) with high and medium intensity 2θ (2 тэта)2θ (2 theta)
5,75.7
12,612.6
15,515,5
17,217,2
20,220,2
26,426,4
2727
и имеет определенную с помощью ДТА среднюю температуру плавления 235 237°С.and has an average melting point of 235,237 ° C. determined by DTA. 3. 8-Циан-1-циклопропил-7-(1S,6S-2,8-диазабицикло[4.3.0]нонан-8-ил)-6-фтор-1,4-дигидро-4-оксо-3-хинолинкарбоновая кислота (CCDC) кристаллической модификации С, полученная таким образом, что CCDC неизвестной модификации или аморфную CCDC выдерживают при относительной влажности не менее 92% без какого-либо приращения веса, затем продукт высушивают и нагревают при температуре, превышающей температуру перехода.3. 8-Cyan-1-cyclopropyl-7- (1S, 6S-2,8-diazabicyclo [4.3.0] nonan-8-yl) -6-fluoro-1,4-dihydro-4-oxo-3- quinoline carboxylic acid (CCDC) of crystalline modification C, obtained in such a way that CCDC of unknown modification or amorphous CCDC is maintained at a relative humidity of at least 92% without any weight gain, then the product is dried and heated at a temperature above the transition temperature. 4. Способ получения CCDC модификации С, отличающийся тем, что CCDC неизвестной модификации или аморфную CCDC выдерживают при относительной влажности не менее 92% без какого-либо приращения веса, затем продукт высушивают и нагревают при температуре, превышающей температуру перехода.4. A method for producing CCDC modification C, characterized in that CCDC of unknown modification or amorphous CCDC is maintained at a relative humidity of at least 92% without any weight gain, then the product is dried and heated at a temperature above the transition temperature. 5. Лекарственное средство, отличающееся тем, что оно содержит наряду с обычными вспомогательными веществами и наполнителями CCDC модификации С по одному из пп.1-3.5. A medicine, characterized in that it contains, along with the usual excipients and excipients of CCDC modification C according to one of claims 1 to 3. 6. Применение CCDC модификации С по одному из пп.1-3 для получения лекарственных средств.6. The use of CCDC modification C according to one of claims 1 to 3 for obtaining medicines. 7. Применение CCDC модификации С по одному из пп.1-3 в антибактериальных средствах.7. The use of CCDC modification C according to one of claims 1 to 3 in antibacterial agents.
RU2001126300/04A 1999-02-26 2000-02-14 8-cyano-1-cyclopropyl-7-(1s,6s-2,8-diazabicyclo-[4,3,0]-nonane-8-yl)-6- flu oro-1,4-dihydro-4-oxo-3-quinoline carboxylic acid of crystalline modification c and medicinal agent eliciting effect against pathogenic microorganisms RU2248356C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19908449.1 1999-02-26
DE19908449A DE19908449A1 (en) 1999-02-26 1999-02-26 Crystal modification C of 8-cyan-1-cyclopropyl-7- (1S, 6S-2,8-diazabicylo- [4.3.0] nonan-8-yl) -6-fluoro-1,4-dihydro-4-oxo 3-chino / incarboxylic acid

Publications (2)

Publication Number Publication Date
RU2001126300A true RU2001126300A (en) 2003-09-20
RU2248356C2 RU2248356C2 (en) 2005-03-20

Family

ID=7899027

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001126300/04A RU2248356C2 (en) 1999-02-26 2000-02-14 8-cyano-1-cyclopropyl-7-(1s,6s-2,8-diazabicyclo-[4,3,0]-nonane-8-yl)-6- flu oro-1,4-dihydro-4-oxo-3-quinoline carboxylic acid of crystalline modification c and medicinal agent eliciting effect against pathogenic microorganisms

Country Status (26)

Country Link
US (1) US6649762B1 (en)
EP (1) EP1155018B1 (en)
JP (1) JP2002538158A (en)
KR (1) KR100756471B1 (en)
CN (1) CN1191253C (en)
AT (1) ATE226952T1 (en)
AU (1) AU763003B2 (en)
BR (1) BR0008493A (en)
CA (1) CA2362801A1 (en)
CZ (1) CZ299700B6 (en)
DE (2) DE19908449A1 (en)
DK (1) DK1155018T3 (en)
ES (1) ES2181644T3 (en)
HK (1) HK1044948B (en)
HU (1) HUP0200006A3 (en)
IL (2) IL144702A0 (en)
NO (1) NO320191B1 (en)
NZ (1) NZ513750A (en)
PL (1) PL349368A1 (en)
PT (1) PT1155018E (en)
RU (1) RU2248356C2 (en)
SK (1) SK285562B6 (en)
TR (1) TR200102434T2 (en)
UA (1) UA70356C2 (en)
WO (1) WO2000052009A1 (en)
ZA (1) ZA200106289B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19854356A1 (en) 1998-11-25 2000-05-31 Bayer Ag Crystal modification A of 8-cyan-1-cyclopropyl-7- (1S, 6S-2,8-diazabicyclo- / 4.3.0 / nonan-8-yl) -6-fluoro-1,4-dihydro-4-oxo 3-quinoline carboxylic acid
DE19854355A1 (en) 1998-11-25 2000-05-31 Bayer Ag Crystal modification B of 8-cyan-1-cyclopropyl-7- (1S, 6S-2,8-diazabicyclo- / 4.3.O / nonan-8-yl) -6-fluoro-1,4-dihydro-4-oxo 3-quinoline carboxylic acid
DE19908448A1 (en) 1999-02-26 2000-08-31 Bayer Ag Crystal modification D of 8-cyan-1-cyclopropyl-7- (1S, 6S-2,8-diazabicylo [4.3.0) nonan-8-yl) -6-fluoro-1,4-dihydro-4-oxo-3 -chino incarboxylic acid
DE19908449A1 (en) * 1999-02-26 2000-08-31 Bayer Ag Crystal modification C of 8-cyan-1-cyclopropyl-7- (1S, 6S-2,8-diazabicylo- [4.3.0] nonan-8-yl) -6-fluoro-1,4-dihydro-4-oxo 3-chino / incarboxylic acid
DE102004015981A1 (en) * 2004-04-01 2005-10-20 Bayer Healthcare Ag New kirstalline form of 8-cyano-1-cyclopropyl-7- (1S, 6S-2,8-diazabicyclo [4.3.0] nonan-8-yl) -6-fluoro-1,4-dihydro-4-oxo 3-quinolinecarboxylic
DE102006049520A1 (en) * 2006-10-20 2008-04-24 Bayer Healthcare Ag Process for the preparation of pradofloxacin

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2676521B2 (en) 1988-03-22 1997-11-17 北陸製薬株式会社 Method for producing quinolone carboxylic acid compound type I crystals
CZ138297A3 (en) 1994-11-18 1997-10-15 Pharmacia & Upjohn Novel physically stable form of solid fluoroquinolone
DE19546249A1 (en) 1995-12-12 1997-06-19 Bayer Ag New crystal modification of 1-cyclopropyl-7 - ([S, S] -2,8-diazabicyclo [4,3,0] non-8-yl) -6-fluoro-1,4-dihydro-8-methoxy-4 -oxo-3-quinoline carboxylic acid hydrochloride (CDCH), process for its preparation and pharmaceutical preparations containing it
BR9707606B1 (en) * 1996-02-23 2010-08-10 8-cyano-1-cyclopropyl-7- (2,8-diazabicyclo (4.3.0) nonan-8-yl) -6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids as well as medicines that understand them.
DE19633805A1 (en) * 1996-02-23 1997-08-28 Bayer Ag Optionally substituted 8-cyano-l-cyclopropyl-7- (2,8-diazabicyclo- [4.3.0] -nonan-8-yl) -6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids and their derivatives
DE19854356A1 (en) 1998-11-25 2000-05-31 Bayer Ag Crystal modification A of 8-cyan-1-cyclopropyl-7- (1S, 6S-2,8-diazabicyclo- / 4.3.0 / nonan-8-yl) -6-fluoro-1,4-dihydro-4-oxo 3-quinoline carboxylic acid
DE19854355A1 (en) 1998-11-25 2000-05-31 Bayer Ag Crystal modification B of 8-cyan-1-cyclopropyl-7- (1S, 6S-2,8-diazabicyclo- / 4.3.O / nonan-8-yl) -6-fluoro-1,4-dihydro-4-oxo 3-quinoline carboxylic acid
DE19908448A1 (en) 1999-02-26 2000-08-31 Bayer Ag Crystal modification D of 8-cyan-1-cyclopropyl-7- (1S, 6S-2,8-diazabicylo [4.3.0) nonan-8-yl) -6-fluoro-1,4-dihydro-4-oxo-3 -chino incarboxylic acid
DE19908449A1 (en) * 1999-02-26 2000-08-31 Bayer Ag Crystal modification C of 8-cyan-1-cyclopropyl-7- (1S, 6S-2,8-diazabicylo- [4.3.0] nonan-8-yl) -6-fluoro-1,4-dihydro-4-oxo 3-chino / incarboxylic acid

Similar Documents

Publication Publication Date Title
RU2006101764A (en) HEAT RESISTANT CRYSTALLINE HYDROCHLORIDE EPIRUBICIN AND METHOD FOR ITS PRODUCTION
DE3711193A1 (en) 5-SUBSTITUTED CHINOLON AND NAPHTHYRIDONE CARBONIC ACID DERIVATIVES
RU2001126300A (en) CRYSTALLINE MODIFICATION C 8-CYAN-1-CYCLOPROPYL-7 (1S, 6S-2,8-DIAZABICYCLO [4.3.0] NONAN-8-IL) -6-FLUOR-1,4-DIGIDRO-4-OXO-3- Quinoline Carboxylic Acid
JP2817907B2 (en) Intermediate for antibacterial agent production
NO901171L (en) PROCEDURE FOR THE PREPARATION OF SUBSTITUTED AZETIDINYLPYRIDONCARBOXYLIC ACID DERIVATIVES.
KR100756471B1 (en) 8-cyano-1-cyclopropyl-7- (1S, 6S-2,8-diazabicyclo [4.3.0] nonan-8-yl) -6-fluoro-1,4-dihydro-4- Crystal Modifier C of oxo-3-quinoline carboxylic acid
KR100740950B1 (en) 8-cyano-1-cyclopropyl-7- (1S, 6S-2,8-diazabicyclo [4.3.0] nonan-8-yl) -6-fluoro-1,4-dihydro-4- Crystal Modifier of Oxo-3-quinoline Carboxylic Acid iii
NO176961C (en) Analogous Process for the Preparation of Therapeutically Active 3-Phenyl-5,6-dihydrobenz [α-acridine-7-carboxylic Acids & Related Compounds
KR100740947B1 (en) 8-cyano-1-cyclopropyl-7- (1S, 6S-2,8-diazabicyclo [4.3.0] nonan-8-yl) -6-fluoro-1,4-dihydro-4- Crystal Modifier A of oxo-3-quinoline carboxylic acid
RU2001117525A (en) CRYSTALLINE MODIFICATION A 8-CYAN-1-CYCLOPROPYL-7- (1S, 6S-2,8-DIAZABICYCLO [4.3.0] NONAN-8-IL) -6-Fluorine-1, 4-DIHYDRO-4-OXO-3 -QINOLINCARBOXYLIC ACID
RU2001126301A (en) CRYSTALLINE MODIFICATION D 8-CYAN-1-CYCLOPROPYL-7- (1S, 6S-2,8-DIAZABICYCLO [4.3.0] NONAN-8-IL) -6-FLUOR-1,4-DIGIDRO-4-OXO-3 -QINOLINCARBOXYLIC ACID
JP2002538158A5 (en)
SK6842001A3 (en) Semi-hydrochloride of 8-cyan-1-cyclopropyl-7-(1s,6s-2,8- diazabicyclo [4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3- quinoline carboxylic acid
SK11942001A3 (en) Crystal modification d of 8-cyano-1-cyclopropyl-7-(1s,6s-2,8- diazabicyclo-[4.3.0] nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3- quinoline carboxylic acid
JP2002538159A5 (en)
MXPA01008651A (en) Crystal modification c of 8-cyano-1-cyclopropyl-7- (1s, 6s-2,8- diazabicyclo -[4.3.0]nonan-8-yl) -6-fluoro-1,4-dihydro-4-oxo-3-quinoline carboxylic
MXPA01005230A (en) Crystal modification a of 8-cyano-1- cyclopropyl -7-(1s,6s-2, 8-diazabicyclo [4.3.0]nonan -8-yl)-6- fluoro-1, 4-dihydro- 4-oxo-3- quinoline carboxylic acid
MXPA01005229A (en) Crystal modification b of 8-cyano-1- cyclopropyl -7-(1s,6s-2, 8-diazabicyclo [4.3.0]nonan -8-yl)-6- fluoro-1,4- dihydro-4- oxo-3-quinoline carboxylic acid
ES2232311A1 (en) Crystalline form of gatifloxacin